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Tumor antigens NY-ESO-1 and p53 both frequently induce spontaneous serum antibody in cancer patients. While NY-
ESO-1-specific CD8
+ and CD4
+ circulating T-cells occur mainly in NY-ESO-1-seropositive patients, p53-specific circulating
CD8
+ and CD4
+ T-cells are respectively undetectable and common in most individuals. Understanding T-cell split
tolerance can help define suitable targets for immunotherapy.
Since its discovery in 1997, we and other
groups have investigated spontaneous
and vaccine-induced immune responses
against NY-ESO-1, a cancer/testis antigen
expressed in many tumor types but not
in somatic healthy tissues.
1 One of the
key immunological characteristics of NY-
ESO-1 is co-induction of spontaneous
antibody, CD4
+, and CD8
+ T cell res-
ponses in cancer patients. Antigens that
induce “integrated immune responses” are
considered ideal targets for immuno-
therapy because adaptive immune subsets
act in a collaborative manner for anti-
tumor responses. Recently, the presence
of integrated immune responses against
NY-ESO-1 was shown to correlate with
better clinical outcome after immunomo-
dulatory treatment with CTLA-4 block-
ade.
2 Additionally, integrated immune
responses against NY-ESO-1 in cancer
patients can be induced or potentiated by
proper vaccination. One limitation of the
use of NY-ESO-1 in cancer immunother-
apy is that its frequency can be low in
individual tumor types and its expression
pattern in tumor is often heterogeneous.
1
Thus, it is important to define other
suitable antigens to expand the applicabil-
ity of immunotherapy.
Another famous candidate for cancer
immunotherapy is p53, a mutational
tumor antigen. Recently, we reported
spontaneous immune responses against
p53 in comparison with those against
NY-ESO-1 in ovarian cancer patients
whose tumors frequently express NY-
ESO-1 and/or accumulate p53 protein.
3
To enable a direct comparison of their
immunogenicity, patients in the same
study cohort were analyzed using the same
experimental procedures for detection of
spontaneous immune responses against
p53 and NY-ESO-1. Circulating p53-
specific serum antibodies were detected
in about 20% of patients, a similar
percentage to NY-ESO-1 serum antibodies
found in this cohort. Remarkably, p53-
specific CD8
+ T cell responses were not
detected in p53-seropositive patients,
nor in seronegative patients or healthy
individuals, yet the same procedure
detected clear NY-ESO-1-specific CD8
+
T cell responses in NY-ESO-1-seropositive
patients in the same study cohort. These
results suggest that the spontaneous activa-
tion and expansion of p53-specific CD8
+
T cells are strictly regulated, likely by
peripheral/central tolerance due to ubi-
quitous expression of wild-type p53 both
in peripheral and thymic antigen present-
ing cells.
On the other hand, p53-specific CD4
+
T cell responses were not only detected in
50% of patients who had p53 antibody,
but also in the majority of seronegative
cancer patients and healthy individuals,
with similar magnitude and epitope
distribution. Importantly, most p53-
specific CD4
+ T cells in healthy donors
were derived from CD45RO
+ memory
T cell population, indicating that they
were primed in vivo. This is in contrast
to NY-ESO-1-specific CD4
+ T cells
which are exclusively naïve in healthy
donors and only readily detectable from
the memory repertoire in NY-ESO-1-
seropositive patients using our proce-
dures.
4 It is unclear whether pre-activated
p53-specific CD4
+ T cells seen in healthy
individuals contribute to immunosurveil-
lance, but they may help the strong and
frequent induction of antibody responses
once the tumor accumulates p53. These
observations indicate that in contrast to
CD8
+ T cells, CD4
+ T-cell tolerance to
p53 is very weak or absent, as demon-
strated in pioneering studies using
wild-type and p53-deficient mice.
5,6 The
difference in incidence of T-cell responses
and tolerance profile between the two
antigens may reflect ubiquitous expression
of p53 in normal tissues vs. testis-restricted
significant expression of NY-ESO-1
(Fig.1). The former results in an onto-
genic process of “split T-cell tolerance,”
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  4limiting the usefulness of p53 for immuno-
therapeutic development.
Through immunomonitoring of other
cancer antigens, we found that spontaneous
CD8
+ T-cell responses against MAGE-A3
and NY-CO-58
7 are also limited when
compared with NY-ESO-1. Indeed, NY-
CO-58, an antigen with low-level expres-
sion in normal tissues but overexpressed
in cancer cells, rarely elicits CD8
+ T-cell
responses but is immunogenic for CD4
+
T cells in cancer patients and healthy
donors alike. Even among cancer-testis
antigens, MAGE-A3 elicits fewer CD8
+
T-cell responses spontaneously or after
vaccination compared with NY-ESO-1.
Why only some tumor antigens such as
NY-ESO-1 are able to strongly induce
functional CD8
+ T-cell responses is still to
be determined. To explain differential
induction of CD8
+ T-cell responses, yet
similar CD4
+ T cell and/or antibody
responses among tumor antigens, under-
standing CD8
+ T cell-specific regulatory
mechanisms is required. Suppression
in the periphery or poor antigen cross-
presentation may lead to attenuated CD8
+
T cell responses, and involvement of
central tolerance has been explored.
Recently, it was demonstrated in a mouse
model that expression of mouse cancer-
testis antigen P1A in thymus limits the
magnitude and avidity of P1A-specific
CD8
+ T cells.
8 Although it was shown that
medullary thymic epithelial cells express
tissue-restricted cancer antigens including
Figure1. Model of spontaneous immune responses against p53 and NY-ESO-1. (A) In the thymus, medullary thymic epithelial cells (mTEC) constitutively
expressing p53 eliminate high-avidity p53-specific CD8
+ T cells, while NY-ESO-1-specific CD8
+ T cells are capable of escaping negative selection. CD4
+
T cell central tolerance appears to have little effect for these antigens. (B) In the periphery of healthy individuals, normal cells upregulate p53 expression
by cellular stress such as UV irradiation, NOS exposure, and malignant transformation, and release p53 protein by cell death. Dendritic cells capture p53
protein and activate CD4
+ T cells. In contrast, the testis-specific expression of NY-ESO-1 limits its spontaneous activation of specific T cells in healthy
individuals. (C) In cancer patients, tumor cells expressing NY-ESO-1 and/or accumulating p53 protein release large amount of antigens that induce T cell
activation and antibody production after uptake by dendritic cells and B cells, respectively.
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9 the quantitative difference
among different antigens is not known.
Because expression of tissue-restricted anti-
gens by AIRE appears to be probabilistic,
10
analyses of expression level at the single
cell level may give further understanding
of the central tolerance of tumor-specific
CD8
+ T cells.
Analyzing spontaneous immune res-
ponses in cancer patients is an efficient
strategy to learn about the immunogeni-
city and immune-regulating mechanisms
of tumor antigens as a preclinical step for
immunotherapy development. Antigen-
specific immunotherapies should also
incorporate strong immunomodulatory
strategies such as anti-CTLA-4, anti-
PD-1, or anti-GITR antibodies that
further enhance the immunogenicity of
tumor antigens. Our study comparing
spontaneous immune responses against
p53 and NY-ESO-1 revealed a critical
difference in the regulation of CD8
+ T cell
responses. Various antigens that are
differently expressed in tumors and normal
tissues have been identified and reported
to be immunogenic using various
immunomonitoring techniques that have
different accuracy and sensitivity. To
identify suitable targets for cancer immu-
notherapy, it is important to compara-
tively re-evaluate the immunogenicity of
candidate antigens using standardized
immunomonitoring techniques, to discover
new targets eliciting integrated immune
responses over split T-cell tolerance.
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